EOM Pharmaceutical Holdings, Inc., through its wholly owned subsidiary EOM Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is focused on developing drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases. Its pipeline includes its lead compound EOM613, an investigational novel dynamically dual-acting immunomodulator. EOM613 is a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects. Human cell culture studies demonstrate that EOM613 can suppress or stimulate monocytes and macrophages depending on the activation state and environment of those key immune cells, resulting in either further activation or suppression. Its pipeline also includes EOM147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of retinal diseases.